Indian Drug Manufacturers' Association

What Indian Drug Manufacturers' Association does

Indian Drug Manufacturers' Association (IDMA) is a private, non-profit trade association founded in 1961 and headquartered at Poonam Chambers, Worli, Mumbai. It represents approximately 1,200 Indian pharmaceutical manufacturers, ranging from small and medium enterprises to large producers, and serves as their collective voice in dealings with domestic regulators (CDSCO, NPPA) and international bodies (US FDA, Department of Pharmaceuticals). Its core function is regulatory liaison and policy advocacy, including facilitating cross-border pharmaceutical supply during shortage events such as the 2026 US FDA ifosfamide request and the Russia morphine raw material coordination.

IDMA's revenue is generated through tiered annual membership fees (Principal Member, Corporate Member, Associate Company Member, Associate Academic Member), recurring subscriptions to its publications (IDMA Bulletin, Indian Drugs journal, Annual Publication, Members Directory), advertisement placement in publications, one-time event registration fees for conventions such as the Pharmaceutical Analysts' Convention (delegate fee Rs. 17,700 including GST) and the AI-Driven Pharma Innovation Summit, and transaction-based fees for UCPMP marketing practice complaint registration (Rs. 1,000 including GST). The organization maintains 251-500 employees, a Secretariat under Secretary General Dr. T S Parmar, and an elected Executive Committee led by National President Bharat N Shah (Managing Director, S. Kant Healthcare Ltd.).

The association's product surface spans four tracks: publications (monthly bulletin, scientific journal, annual report, member directory), events (Pharmaceutical Analysts' Convention, AI-Driven Pharma Innovation Summit, National cGMP Day), regulatory advocacy and legal representation (e.g., 2026 Bombay High Court win on price control exemption for drug delivery systems), and compliance services (UCPMP complaint platform, GMP standards coordination, narcotics export data compilation for 1,200 members). Distribution is primarily through direct member communication via website, circulars, advisories, and state boards including Telangana, with no external investors or PE/VC ownership as a member-governed body.

Name

Indian Drug Manufacturers' Association

Legal name

Indian Drug Manufacturers' Association

Website

https://idma-assn.org

Company type

Private

Founded year

1961

Operating status

Operating

Headcount range

101–250 employees

Short description

Indian Drug Manufacturers' Association is a 1961-founded non-profit trade association representing 1,200 Indian pharmaceutical manufacturers, providing regulatory liaison with CDSCO, US FDA, and the Department of Pharmaceuticals, alongside publications, events, and industry advocacy.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro industry

PRIMARYBPADANAJ

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation

Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

Keywords

• Pharmaceutical industry association
• Regulatory advocacy services
• Pharmaceutical trade publications
• Industry convention events
• Trade membership services

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Fees: Annual membership subscriptions from pharmaceutical manufacturer members, with different tiers including Principal Member, Corporate Membership, Associate Company Member, and Associate Academic Member
2. Publications: Subscription to IDMA Bulletin, Indian Drugs journal, Annual Publication, and Members Directory
3. Event Registration: Registration fees for seminars, conferences, webinars, and conventions such as the Pharmaceutical Analysts' Convention and AI-Driven Pharma Innovation Summit
4. Advertisement: Advertisement space in IDMA Publications
5. UCPMP Complaint Registration: Fee for registering Uniform Code for Pharmaceutical Marketing Practices complaints (Rs. 1,000 including GST)

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Indian Drug Manufacturers' Association (IDMA) is a non-profit trade association that represents 1,200 Indian pharmaceutical manufacturing companies. It provides industry representation, regulatory liaison with bodies such as CDSCO, US FDA, and NPPA, advocacy on GMP standards and price controls, and delivers membership services including publications (IDMA Bulletin, Indian Drugs journal, Annual Publication, Members Directory), industry conventions (Pharmaceutical Analysts' Convention, AI-Driven Pharma Innovation Summit), and a UCPMP complaint registration platform.

Product overview

IDMA operates as an industry association offering a platform of publications, events, and membership services to its 1,200 member pharmaceutical companies. The core offerings include IDMA Bulletin and Indian Drugs journals, an Annual Publication, Members Directory, Pharmaceutical Analysts' Convention (PAC), AI-Driven Pharma Innovation Summit, UCPMP Complaint Registration service, and various membership tiers. The association serves as a regulatory liaison between pharmaceutical manufacturers and government bodies including CDSCO, NPPA, and US FDA.

Differentiator

Problem solved

Functional benefit

Brands

• IDMA Bulletin: Official publication of IDMA providing industry updates and news
• Indian Drugs
• IDMA Pharmaceutical Analysts' Convention (PAC)
• IDMA 3rd National cGMP Day

Products and services

• IDMA Bulletin Monthly publication containing industry news, regulatory updates, and pharmaceutical market intelligence for member companies and industry professionals.
• Indian Drugs Scientific pharmaceutical journal covering drug research, development, and regulatory affairs, targeted at pharmaceutical researchers and industry professionals.
• Annual Publication Annual report covering pharmaceutical industry statistics, regulatory developments, and association activities for member companies and stakeholders.
• Members Directory Directory listing IDMA member companies with contact details and business information, used by pharmaceutical industry stakeholders for networking and business development.
• Pharmaceutical Analysts' Convention (PAC) Annual convention for pharmaceutical quality, technical, production, and regulatory affairs professionals covering compliance, innovation, and industry best practices.
• AI-Driven Pharma Innovation Summit Summit focused on AI applications in pharmaceutical manufacturing, drug discovery, and digital transformation, bringing together industry leaders, scientists, technology experts, and policymakers.
• UCPMP Complaint Registration Service for registering complaints related to violations of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), with a non-refundable registration fee of Rs. 1,000 including GST.
• IDMA Membership Annual membership program with categories including Principal Member, Corporate Member, Associate Company Member, and Associate Academic Member, providing pharmaceutical manufacturers access to publications, events, regulatory advocacy, and industry representation.

Quantifiable outcome

• Coordinated response to US FDA request for ifosfamide supply within days of request

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered core and minor.

• Indian Department of PharmaceuticalscoreStrategic or Co-development Partner · 6 July 2026The Department of Pharmaceuticals wrote to IDMA to identify exporters capable of supplying morphine raw material to Russia for battlefield medical care. IDMA is compiling data from its 1,200 member companies on names, facility locations, products, and existing export markets.
• US FDA India OfficecoreGTM or Marketing Partner · 18 June 2026The US FDA's India Office approached IDMA to identify Indian pharmaceutical manufacturers capable of supplying ifosfamide injection during a drug shortage crisis caused by Baxter International's manufacturing disruption and West Asia conflict supply chain issues. IDMA facilitates connections between capable manufacturers and the regulatory body.
• Indian Pharmacopoeia CommissioncoreStrategic or Co-development Partner · 10 April 2026IDMA is an industry stakeholder reviewing draft guidelines proposed by the Indian Pharmacopoeia Commission regarding cough syrup regulations for children under 2 years and other drug safety matters.
• Operant Pharmacy FederationminorStrategic or Co-development Partner · 22 January 2026Co-organized the AI-Driven Pharma Innovation Summit 2026 held January 22-23, 2026 in Hyderabad, India, focusing on AI applications in drug discovery, Pharma 4.0 to Pharma 5.0 transition, smart manufacturing, and quantum-ready solutions.
• Chronicle PharmabizminorStrategic or Co-development Partner · 22 January 2026Co-organized the AI-Driven Pharma Innovation Summit 2026 with other industry bodies, serving as a platform for industry dialogue on AI-enabled innovation and digital excellence.
• PharmabharathminorStrategic or Co-development Partner · 22 January 2026Co-organized the AI-Driven Pharma Innovation Summit 2026, bringing together pharmaceutical industry leaders, scientists, technology experts, and policymakers.
• ZydusminorOthersIndian pharmaceutical company identified as being in advanced discussions to supply ifosfamide injection to the US market, coordinated through IDMA's facilitation with US FDA.
• CiplaminorOthersIndian pharmaceutical company contacted by US FDA through IDMA as a potential supplier for ifosfamide injection to address US drug shortage.
• Alkem LaboratoriesminorOthersIndian pharmaceutical company identified as potential supplier for ifosfamide injection following US FDA request coordinated through IDMA.
• Aurobindo PharmaminorOthersIndian pharmaceutical company identified as potential manufacturer for ifosfamide injection as part of IDMA-facilitated response to US FDA shortage request.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Association for Accessible Medicines (AAM): US trade association representing generic and biosimilar manufacturers. Comparable to IDMA in representing generic drug manufacturers, though focused on the US market and policy environment.
• Pharmaceutical Research and Manufacturers of America (PhRMA): The leading US pharmaceutical industry trade association representing major research-based drug manufacturers. Comparable as a pharma industry body, though focused on US/international R&D-driven manufacturers rather than India's generic manufacturing base.
• Organization of Pharmaceutical Producers of India: Represents research-based pharmaceutical companies in India, including multinational R&D-driven manufacturers. Directly competes with IDMA for membership and influence over Indian pharmaceutical policy, particularly on IP, clinical research, and international trade matters.
• Indian Pharmaceutical Association: A national pharmaceutical association in India representing pharmacists and pharmaceutical professionals. While its focus is more on pharmacy practice than manufacturing, it overlaps with IDMA in representing India's broader pharmaceutical sector and engages with similar regulatory bodies (CDSCO, NPPA).

Broad incumbents

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): A global pharmaceutical industry association based in Geneva representing R&D-based pharma companies and associations worldwide. Comparable as a pharma trade body operating at the international regulatory level, similar to IDMA's liaison role with US FDA.
• European Federation of Pharmaceutical Industries and Associations (EFPIA): The umbrella trade association for the European pharmaceutical industry, representing both research-based and generic manufacturers. Comparable to IDMA as a continental pharma trade body, though larger in scope and global influence.

Others

• Indian Drug Manufacturers' Association - not applicable: Placeholder removed - see other entries.

Regional players

• Japan Pharmaceutical Manufacturers Association (JPMA): Japan's leading pharmaceutical industry trade association representing both domestic and international pharma companies. Comparable to IDMA as a national pharma trade body, though serving a more R&D-focused and higher-income market.
• China Pharmaceutical Industry Association: National trade association representing pharmaceutical manufacturers in China. Comparable to IDMA as a major emerging-market pharma industry body serving generic and innovative drug manufacturers, with similar advocacy roles vis-à-vis Chinese regulators.

Emerging players

• Bulk Drug Manufacturers Association of India (BDMAI): An Indian trade association representing bulk drug (API) manufacturers. Comparable to IDMA as a domestic Indian pharma trade body but focused specifically on the API manufacturing segment, providing overlapping but narrower representation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indian Drug Manufacturers' Association